iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Cipla's Patalganga plant gets Voluntary Action Indicated (VAI) from USFDA

25 Jun 2024 , 01:51 PM

Cipla Ltd., a Mumbai-based medicine producer, has informed the exchanges that its Patalganga manufacturing plant has earned Voluntary Action Indicated status from the US Food and medicine Administration (USFDA).

The Patalganga facility received a form 483 with six observations from the regulator in April of this year.

A Voluntary Action Indicated (VAI) status indicates that undesirable circumstances or procedures were discovered at the facility, but the agency (USFDA) does not intend to take or propose any administrative or regulatory action. It is lower than Official Action Indicated (OAI), implying that regulatory and/or administrative steps are recommended.

From March 28 to April 4, 2024, the US drug regulator conducted a normal current Good Manufacturing Practices (cGMP) inspection at the site.

Cipla’s Patalganga factory develops both Active Pharmaceutical Ingredients (APIs), the primary raw components for medications, and formulations.

The USFDA recently inspected Cipla’s Goa factory and issued six observations. The aforementioned unit has been issued a warning notice since February 2020. The Goa facility was inspected between June 10 and 21, 2024.

Cipla’s Indore factory has been under a warning notice since November 2023.

Cipla also inked a non-exclusive patent license arrangement with Takeda last week for the medicine Vonoprazan in the Indian market. The medicine is intended to treat people suffering from acid-related disorders.

At around 1.25 PM, Cipla was trading 0.44% lower at ₹1,497.85 per piece, against the previous close of ₹1,504.40 on NSE. The counter touched an intraday high and low of ₹1,517, and ₹1,496, respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Cipla
  • Cipla news
  • Cipla share price
  • Cipla Updates
  • Cipla USFDA
  • Cipla VAI
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.